How long do cancer patients live with SUTENT?

The survival duration for cancer patients treated with Sutent (sunitinib malate) varies based on the type of cancer and individual patient factors.   
 
Renal Cell Carcinoma (RCC): Patients treated with Sutent have shown a median progression-free survival of approximately 11 months, compared to 5 months for those receiving interferon α (IFNα).  
 
Gastrointestinal Stromal Tumors (GIST): Sutent has been shown to delay tumor progression by about 21 weeks, with a median progression-free survival of 24.1 weeks compared to 6 weeks for placebo.  
 
Pancreatic Neuroendocrine Tumors (pNET): The median progression-free survival for patients with pNET treated with Sutent is around 10.2 months, compared to 5.4 months with placebo.  
 
Adjuvant Treatment of RCC: In high-risk patients after nephrectomy, Sutent has demonstrated a median disease-free survival of approximately 6.8 years, significantly longer than the placebo group.

Leave a Reply

Your email address will not be published. Required fields are marked *

Free Delivery

Free shipping on all order

Money Return

Guarantee under 7 days

Member Discount

On every order over PKR1000.00

Support 24/7

Support online 24 hours a day

Onlinepharmacy.pk is an online medicine store in Pakistan that lets you shop anytime, 24/7. It’s a popular choice for buying medical supplies and delivers all across Pakistan.

Useful Links

Info Links

Follow us on:

Contact

main shahr-e-faisal, karachi
Phone: 03052556094
Email: Ibneahmed83@gmail.com

Delivery Partners:

Payment Methods:

2024 © All Rights Reserved @ onlinepharmacy.Pk 

Add to cart